Item 7.01 Regulation FD Disclosure.

Beginning January 6, 2021, officers of the Company will present to various investors and stockholders using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.





Item 8.01

On January 5, 2021, Enzo Biochem, Inc. (the "Company") issued a press release titled "Enzo Biochem to Participate in the LifeSci Partners 10th annual Healthcare Corporate Access Event". A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
99.1            Presentation materials to be used by officers of the Company
99.2            Press Release of Enzo Biochem, Inc., dated January 5, 2021




                                       1

© Edgar Online, source Glimpses